Country: Canada
Language: English
Source: Health Canada
EMTRICITABINE; RILPIVIRINE (RILPIVIRINE HYDROCHLORIDE); TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
GILEAD SCIENCES CANADA INC
J05AR19
EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND RILPIVIRINE
200MG; 25MG; 25MG
TABLET
EMTRICITABINE 200MG; RILPIVIRINE (RILPIVIRINE HYDROCHLORIDE) 25MG; TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE) 25MG
ORAL
30
Prescription
NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
Active ingredient group (AIG) number: 0358830001; AHFS:
APPROVED
2017-02-10
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ODEFSEY ® (EMTRICITABINE/RILPIVIRINE/TENOFOVIR ALAFENAMIDE) TABLETS 200 mg emtricitabine 25 mg rilpivirine (as rilpivirine hydrochloride) 25 mg tenofovir alafenamide (as tenofovir alafenamide hemifumarate) ANTIRETROVIRAL AGENT Gilead Sciences Canada, Inc. Mississauga, ON L5N 2W3 www.gilead.ca Submission Control No: 229507 Date of Initial Approval: February 10, 2017 Date of Revision: November 13, 2019 ODEFSEY (emtricitabine/rilpivirine*/tenofovir alafenamide**) tablets *as rilpivirine hydrochloride **as tenofovir alafenamide hemifumarate Product Monograph _ _ _ _ _Page 2 of 97_ RECENT MAJOR LABEL CHANGES Serious Warnings and Precautions Box (3) 06/2018 Dosage and Administration, Dosing Considerations (4.1) 10/2019 Dosage and Administration, Recommended Dose and Dose Adjustment (4.2) 12/2018 Warnings and Precautions, General (7) 10/2019 Warnings and Precautions, Cardiovascular (7) 10/2019 Warnings and Precautions, Serum Lipids and Blood Glucose (7) 06/2018 Warnings and Precautions, Gastrointestinal (7) 01/2018 Warnings and Precautions, Lactic Acidosis/Severe Hepatomegaly with Steatosis (7) 06/2018 Warnings and Precautions, Musculoskeletal (7) 06/2018 Warnings and Precautions, Renal (7) 10/2019 Warnings and Precautions, Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions (7) 10/2019 Warnings and Precautions, Special Populations, Pregnant Women (7.1.2) 12/2018 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ........................................................................................................... 2 TABLE OF CONTENTS ................................................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................................... 4 1. INDICATIONS .................................................................................................................................... Read the complete document